As a consequence, a combinatorial treatment with the chemotherapeutic agent docetaxel and the ETA inhibitor ABT-627 leads to a reduced prostate tumor growth within the bone marrow of mice via suppression of the AKT/NFKB axis [148]. This evidence concerns the gene AKT1 and prostate neoplasm.